Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer's Disease Intervention: What Evidence is Meaningful to Patients, Providers, and Payers?

The journal of prevention of Alzheimer's disease·2018
Same author

Controlled trial of interventions to increase testing and treatment for Helicobacter pylori and reduce medication use in patients with chronic acid-related symptoms.

Alimentary pharmacology & therapeutics·2005
Same author

Improvements in medicare coverage of new technology.

Health affairs (Project Hope)·2001
Same author

Lansoprazole compared with histamine2-receptor antagonists in healing gastric ulcers: a meta-analysis.

Clinical therapeutics·1997
Same author

Practice guidelines. What are internists looking for?

Journal of general internal medicine·1996
Same author

Users' guides to the Medical Literature. VIII. How to use clinical practice guidelines. B. what are the recommendations and will they help you in caring for your patients? The Evidence-Based Medicine Working Group.

JAMA·1995

Related Experiment Video

Updated: May 24, 2026

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

Current and future state of FDA-CMS parallel reviews.

D A Messner1, S R Tunis

  • 1Center for Medical Technology Policy, World Trade Center-Baltimore, Baltimore, Maryland, USA. donna.messner@cmtpnet.org

Clinical Pharmacology and Therapeutics
|February 21, 2012
PubMed
Summary

The US Food and Drug Administration (FDA) and Centers for Medicare and Medicaid Services (CMS) proposed parallel review for medical products. This aims to speed up market access and Medicare coverage, incentivizing developers to meet diverse stakeholder needs.

More Related Videos

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
10:17

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

Related Experiment Videos

Last Updated: May 24, 2026

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
10:17

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

Area of Science:

  • Health policy
  • Medical product regulation
  • Healthcare economics

Background:

  • The US Food and Drug Administration (FDA) and Centers for Medicare and Medicaid Services (CMS) have historically operated separate review processes for new medical products.
  • This separation can lead to delays in market availability and patient access to innovative therapies.
  • Aligning review pathways is crucial for streamlining the medical product lifecycle.

Purpose of the Study:

  • To introduce and explain the proposed "parallel review" process between the FDA and CMS.
  • To highlight the potential benefits of this aligned review for medical product developers and patients.
  • To discuss the implications for study design and data generation in medical product development.

Main Methods:

  • The abstract describes a proposed policy change, not an empirical study.
  • It outlines the concept of parallel review, where FDA and CMS review processes are partially aligned.
  • The focus is on the potential impact and incentives created by this proposed alignment.

Main Results:

  • The parallel review process may expedite market entry for certain medical products.
  • It offers the potential for faster Medicare coverage decisions.
  • New incentives may encourage product developers to generate data addressing the needs of regulators, payers, patients, and clinicians simultaneously.

Conclusions:

  • The proposed parallel review represents a significant policy shift in medical product evaluation.
  • This initiative has the potential to improve efficiency and coordination between regulatory and reimbursement bodies.
  • It could foster the development of products that better meet the comprehensive needs of the healthcare ecosystem.